Raman Process Monitoring Patents: Leaders & White Space 2026
- Concentrated but not locked up. the top 5 assignees hold 36.9% of all 249 records in scope, and the top 10 hold 53.4% — a real lead but well short of a closed field.
- Filing has cooled from its 2017 peak. 23 records that year versus 6 in the most recent (partial) year, with the complete 2021-2024 window down 15%.
- Diagnostics overlap is heavier than optics hardware. A61B diagnosis-and-surgery classes touch 22.5% of records, ahead of G02B optical-element classes at 6.0%, showing where drift-correction claims are actually being written for.
Filing growth compares 2021 (13 records) with 2024 (11) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 249 records in scope (CR5), not by the ranked leaders only.
What this patent set covers
This landscape tracks patents and applications where Raman spectroscopy, Raman probes or Raman monitoring are claimed alongside drift-management mechanisms: reference standards, drift detection, online correction, temperature effects, probe aging or recalibration intervals. The scope is defined by IPC classes G01N21/65, C12Q3/00 and G01N21/359, covering material analysis, enzymatic/DNA measurement and light-scattering optics respectively. 249 records published between 2015 and mid-2026 make up the dataset.
Because publication trails filing by roughly 18 months, the most recent one to two years in any trend chart will understate real filing activity — treat the tail as provisional, not as a slowdown signal on its own.
Filing trend and technology composition
Two views of the same 249-record set: how filing volume has moved year over year, and which IPC subclasses the claims actually sit in.
Filing trend: a 2017 peak followed by a cooler plateau
Filings peaked at 23 in 2017. The last fully countable year, 2024, sits at 11 — down 15% from 13 in 2021, a real but moderate pullback rather than a collapse. Years after 2024 will keep rising in the data as publications catch up.
Technology composition: diagnostics claims outweigh pure optics
Every record sits in G01N (material analysis) by definition of the search. Beyond that, G01J light-measurement classes touch a third of records (33.3%), A61B diagnosis-and-surgery classes touch 22.5%, and the remaining classes — C12Q, G02B, B82Y, G06N, C12N — each cover single-digit-to-low-double-digit shares, pointing to smaller but distinct sub-clusters around enzymatic assays, nanophotonics and AI-assisted correction.
Shares are the percentage of the 249 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Raman Process Monitoring Drift Compensation with Eureka
This page is one run against one query. Ask Eureka your own question about raman process monitoring drift compensation and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative filing and the most-cited prior art
Probe head, Raman spectroscopy instrument comprising the probe head, and method of performing optical measurements (WO2026098976A1)
The filing describes a probe head with an internal reference-target selector that can be switched into the optical pathway so the returning signal originates from a target of known Raman spectrum rather than the sample — a built-in, switchable calibration reference rather than an external standard swapped in by an operator.Filed by Mettler-Toledo GmbH, published 2026-05-15.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5866430A | Raman optrode processes and devices for detection of chemicals and microorganisms | 412 |
| 2 | US5953477A | Method and apparatus for improved fiber optic light management | 299 |
| 3 | US6222970B1 | Methods and apparatus for filtering an optical fiber | 244 |
| 4 | US9554738B1 | Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using coll… | 178 |
| 5 | US20160097716A1 | Systems and methods for blood glucose and other analyte detection and measurement using collision computing | 166 |
| 6 | US6370406B1 | Method and apparatus for analyzing a test material by inducing and detecting light-matter interactions | 158 |
| 7 | US6366726B1 | Fiber optic probes for indwelling investigations | 156 |
| 8 | US20010012429A1 | Method and apparatus for improved fiber optic light management | 153 |
| 9 | US20040127778A1 | Identifying or measuring selected substances or toxins in a subject using resonant raman signals | 134 |
| 10 | US6621574B1 | Dual function safety and calibration accessory for raman and other spectroscopic sampling | 124 |
Citation counts favour older filings simply because they have had longer to accumulate citations inside this corpus — read them as a signal of influence on the field, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for filing strategy
Three read-throughs from the numbers above, aimed at where to file next and where prior art is thinnest.
A lead, not a lock
The leading assignee holds 36 records and the field drops off quickly after that — fifth place sits at 12, tenth at 7. That gap between the leader and the rest means freedom-to-operate work has to look past just the top name; the ranked list runs to 91 companies, most with only a handful of filings each.
A mature plateau, not a rush
The -15% move from 2021 to 2024 is a moderate cooling from a 2017 peak of 23, not evidence of an abandoned field. Recent-year momentum by individual assignee reads flat across the leaders shown in the data, which fits a field where core mechanisms are claimed and activity has shifted toward incremental filings.
Diagnostics claims outnumber pure hardware claims
A61B (diagnosis and surgery) touches over a fifth of records, well ahead of G02B (optical elements and systems) at 6.0%. That asymmetry suggests drift-compensation inventions are being framed more often around clinical or bio-analyte measurement contexts than around standalone probe optics.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to raman process monitoring drift compensation, with the prior art for and against each one.
Who is filing, and where the gaps sit
The assignee ranking spans 91 companies rather than a small closed group, with co-filing activity concentrated around a handful of research-institution pairs.
One clear leader, then a fast drop-off
The top assignee holds 36 of the 249 records, more than double the fifth-place count of 12. That gap is wide enough to matter for competitive tracking, but it does not amount to control of the field given how many single- and double-digit filers follow.
Research-institution pairs dominate co-filing
The strongest co-assignee links run through a small number of research-institution and hospital pairings rather than industrial joint ventures, with the top pair appearing together 12 times.
A long tail of narrow filers
Beyond the top ten, the ranking runs to 91 companies, most holding only a few records each. That tail is where niche instrumentation and single-application claims live, and where freedom-to-operate searches often turn up the sharpest, most specific prior art.
| Assignee | Recent year | YoY |
|---|---|---|
| ONDAVIA INC | 0 | — |
| Zyomed Holdings Inc | 0 | — |
| California Institute of Technology | 0 | — |
| National University of Singapore | 0 | — |
| Children's Hospital of Los Angeles | 0 | — |
| Ortho McNeil Pharmaceutical Inc | 0 | — |
| Johnson Matthey PLC | 0 | — |
| CIRREX CORP | 0 | — |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, licensing or new filing.
Run a freedom-to-operate check on the leader's claims
With the top assignee holding 36 of 249 records, a claim-by-claim review of its reference-standard and recalibration mechanisms is the first filter before drafting anything adjacent.
Explore assignee claims in EurekaMap the under-claimed branches against your own roadmap
AI-assisted correction, probe-aging compensation and nanophotonic references show comparatively thin direct coverage — worth a closer novelty search before assuming the space is open.
Run a white-space search in EurekaTrack co-filing patterns among research institutions
The strongest co-assignee pairs are institution-hospital links rather than corporate partnerships, which may signal where licensing-in opportunities sit rather than where competitors are.
Trace collaboration networks in EurekaCommon questions on this landscape
This dataset identifies 249 published records between 2015 and mid-2026 that combine Raman spectroscopy, probe or monitoring claims with drift-management elements such as reference standards, drift detection, temperature correction or recalibration intervals. That figure is the whole scoped set returned by the search string and IPC filter used for this analysis, not a broader count of every Raman patent. Because publication lags filing by roughly 18 months, the true number of filings in the most recent one to two years will be higher once later publications catch up.
The assignee ranking covers 91 companies and research institutions, with the leader holding 36 of the 249 records in scope. Filing count drops quickly after the leader, with fifth place at 12 records and tenth place at 7, so the field has one clear front-runner followed by a long tail of smaller filers rather than a tight cluster of equally matched competitors. Reviewing the leader's specific claim mechanisms is the practical starting point for any freedom-to-operate work.
Filing peaked in 2017 at 23 records and, across the last fully countable years, moved from 13 in 2021 to 11 in 2024 — a 15% decline over that span. That reads as a plateau after an early peak rather than either a boom or an abandoned field. Figures for 2025 and 2026 will rise as publications catch up, so they should not be read as a further drop yet.
Beyond the core G01N material-analysis classification that defines the search, G01J light-measurement classes appear in 33.3% of the 249 records and A61B diagnosis-and-surgery classes in 22.5%, making clinical and bio-analyte applications a bigger overlap than pure optical hardware. Smaller but distinct clusters sit in C12Q enzymatic/DNA testing, G02B optical elements, B82Y nanotechnology and G06N AI-based computing, each in the single digits. These smaller classes are worth checking individually since a record can carry more than one class.
The technology composition data shows AI-assisted correction (G06N), nanophotonic reference substrates (B82Y) and enzymatic/DNA-assay drift calibration (C12Q) each covering under 7% of the 249 records, well behind the core optical and diagnostic clusters. That does not guarantee an open field, but it does mean claim density there is far lower than around the core reference-standard and recalibration mechanisms the leading assignees already hold. A targeted novelty search on those specific branches is the sensible next step before drafting.
Research Raman Process Monitoring Drift Compensation in depth with Eureka
Go past this page: query the whole raman process monitoring drift compensation corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.